Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Oddzial Kliniczny Hematologii

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with the company's drug candidates like Emavusertib and Fimepinostat. The content serves as a comprehensive resource for investors and stakeholders interested in Curis's operations and research initiatives.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · clean, no other CRIS news in the window
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the focus of Curis's current studies?

Curis is currently focused on studies like TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What are the main drug candidates in Curis's pipeline?

Curis's pipeline includes drug candidates such as Emavusertib (CA-4948) and Fimepinostat.

Who is part of the Curis management team?

The management team includes a Board of Directors and various advisory boards.

What collaborations does Curis engage in?

Curis engages in partner collaborations and scientific research collaborations.

How can I find financial information about Curis?

Financial information about Curis can be found in their SEC filings and annual reports.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis TakeAim Lymphoma Emavusertib Fimepinostat CA-4948
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →